5-Amino-1MQ dosing — commonly cited oral range

There is no validated 5-Amino-1MQ dosage — no human study has ever established one. The numbers in circulation are community conventions: vendors and forums typically cite roughly 50 mg once daily by mouth, with some accounts describing 100–150 mg per day, usually as capsules and often framed as multi-week cycles. Those figures describe marketplace habit, not evidence — and because this is an oral compound with unmeasured absorption, even a consistent milligram habit does not mean a consistent exposure.

• ~50 mg once daily is the most frequently mentioned starting figure.
• Some accounts describe working up toward ~100–150 mg per day.
• Taken orally, once daily, commonly in defined cycles rather than indefinitely.

These amounts vary between sources and have no clinical anchor. Unlike peptides with at least a trial protocol to point to, 5-Amino-1MQ's numbers cannot be traced to any human study, because none exists. The "cycle" convention deserves the same scrutiny: cycling is a habit imported from hormonal compounds, where receptors downregulate — nothing published about NNMT inhibition establishes that on-off scheduling is needed, helpful, or harmful. It is structure borrowed for the feeling of structure.

The peer-reviewed studies used a very different scheme from the capsules sold online. The obesity experiment gave diet-induced obese mice 20 mg/kg by subcutaneous injection, three times daily, for 11 days (Biochemical Pharmacology 2018), and the aged-mice muscle study ran NNMT-inhibitor treatment for two months (Scientific Reports 2024). Injected, weight-based, multiple-times-daily lab dosing is not the same intervention as a once-daily oral capsule, even when the molecule matches.

Converting animal doses to human ones is not simple arithmetic. Mice metabolize drugs faster per kilogram, allometric scaling changes the numbers severalfold, and — most importantly here — 5-Amino-1MQ's human oral bioavailability has never been measured. A swallowed milligram amount tells you nothing reliable about blood levels when no one has published human absorption, distribution, or clearance data. Vendors sometimes present "human-equivalent dose" calculations from the mouse work to make their capsule strengths look derived; without measured human absorption, that arithmetic produces confident-looking numbers from missing inputs. The community's 50–150 mg range is therefore a guess layered on a guess: an unvalidated exposure of an untested compound. A real dose would come from a phase 1 program — ascending doses, blood sampling, tolerability monitoring — which is exactly the work nobody has done.

With no human data, no one can say what amount is safe or effective, what months of NNMT inhibition do, or how the compound interacts with other medicines and conditions. A clinician cannot look up an answer that doesn't exist — but they can screen for risk, watch for adverse effects, and provide the judgment a research chemical's label cannot. The numbers above describe what people say, not a recommendation. For fuller context, see the main 5-Amino-1MQ reference page and the safety guide.